文献速递核素与放射性配体治疗肿瘤 PET/CT

一种用于转移性黑色素瘤靶向α治疗的211At标记α-黑素细胞刺激素肽类似物

An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-01-20

本研究设计了一种经亲水性连接子偶联的211At标记α-MSH肽类似物[211At]NpG-GGN4c,用于转移性黑色素瘤的靶向α治疗。在B16F10荷瘤小鼠中,该化合物肿瘤摄取与125I标记对照物相当,并呈剂量依赖性抑制肿瘤生长且无明显体重下降。

要点

  • D-Glu-D-Arg连接子因对MC1R高亲和力及肝肠低摄取被确定为最优亲水性连接子。
  • [211At]NpG-GGN4c肿瘤摄取与[125I]NpG-GGN4b相当,注射后1至3小时维持肿瘤放射性滞留。
  • [211At]NpG-GGN4c对B16F10移植瘤生长呈剂量依赖性抑制,无明显体重下降。

核心结论

  • [211At]NpG-GGN4c对B16F10移植瘤显示剂量依赖性疗效,提示其是治疗转移性黑色素瘤有前景的靶向α治疗药物。

研究设计与样本

  • 本研究为动物实验研究,使用B16F10荷瘤小鼠评价[211At]NpG-GGN4c。
  • 先以125I标记α-MSH类似物进行初步研究以筛选合适亲水性连接子,再制备[211At]NpG-GGN4c并与[125I]NpG-GGN4b比较生物分布。
  • 治疗实验中将B16F10荷瘤小鼠单次给予溶媒或[211At]NpG-GGN4c(1或0.4 MBq)。

主要发现

  • D-Glu-D-Arg连接子因对MC1R高亲和力及良好生物分布(尤其肝和肠道低蓄积)被确定为最优亲水性连接子。
  • [211At]NpG-GGN4c的肿瘤蓄积与[125I]NpG-GGN4b相当,并维持注射后1至3小时的肿瘤放射性滞留。
  • [211At]NpG-GGN4c对B16F10移植瘤生长呈剂量依赖性抑制作用,且无明显体重下降。

关键数值与推荐

  • 治疗实验单次给药剂量为1或0.4 MBq [211At]NpG-GGN4c。
  • 生物分布比较显示[211At]NpG-GGN4c肿瘤蓄积与[125I]NpG-GGN4b相当。
  • 肿瘤放射性滞留观察时间为注射后1至3小时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients who develop metastatic melanoma have a very poor prognosis, and new treatments are needed to improve the response rates. Melanocortin-1 receptor (MC1R) is a promising target for radionuclide therapy of metastatic melanoma, and alpha-melanocyte stimulating hormone (α-MSH) peptide analogs show high affinities to MC1Rs. Because targeted alpha therapy (TAT) can be a desirable treatment for metastatic melanoma, this study aimed to develop an 211At-labeled α-MSH peptide analog for TAT of metastatic melanoma. METHODS: We designed an α-MSH analog labeled with 211At using a neopentyl glycol scaffold via a hydrophilic linker. Preliminary studies using 125I-labeled α-MSH analogs were performed to identify suitable hydrophilic linkers. Then, [211At]NpG-GGN4c was prepared using a procedure similar to that of the 125I-labeled counterpart, [125I]NpG-GGN4b. The biodistribution profile of [211At]NpG-GGN4c in B16F10 tumor-bearing mice was compared with that of [125I]NpG-GGN4b. B16F10 tumor-bearing mice were treated with a single dose of vehicle or [211At]NpG-GGN4c (1 or 0.4 MBq). RESULTS: The D-Glu-D-Arg linker was identified as the optimal hydrophilic linker because of its high affinity for MC1R and good biodistribution profile, especially with low accumulation in the liver and intestine. [211At]NpG-GGN4c showed tumor accumulation comparable to that of [125I]NpG-GGN4b and maintained the tumor radioactivity retention from 1 to 3 h postinjection. [211At]NpG-GGN4c exhibited a dose-dependent inhibitory effect on B16F10 xenograft growth without apparent body weight loss. CONCLUSION: [211At]NpG-GGN4c showed dose-dependent efficacy against B16F10 xenografts, suggesting that [211At]NpG-GGN4c is a promising TAT agent for treating metastatic melanoma.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Suzuki H, Yamashita S, Tanaka S, et al. An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma. Eur J Nucl Med Mol Imaging. 2025. PMID: 39828865. doi:10.1007/s00259-024-07056-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。